These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35503397)

  • 1. Targeting SMYD2 inhibits angiogenesis and increases the efficiency of apatinib by suppressing EGFL7 in colorectal cancer.
    Zhang Y; Zhou L; Xu Y; Zhou J; Jiang T; Wang J; Li C; Sun X; Song H; Song J
    Angiogenesis; 2023 Feb; 26(1):1-18. PubMed ID: 35503397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMYD2 epigenetically activates MEX3A and suppresses CDX2 in colorectal cancer cells to augment cancer growth.
    Pan L; Fan Y; Zhou L
    Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):959-969. PubMed ID: 35637161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
    Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
    Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation.
    Zhang X; Tanaka K; Yan J; Li J; Peng D; Jiang Y; Yang Z; Barton MC; Wen H; Shi X
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17284-9. PubMed ID: 24101509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase.
    Abu-Farha M; Lambert JP; Al-Madhoun AS; Elisma F; Skerjanc IS; Figeys D
    Mol Cell Proteomics; 2008 Mar; 7(3):560-72. PubMed ID: 18065756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lysine methyltransferases SET and MYND domain containing 2 (Smyd2) and Enhancer of Zeste 2 (Ezh2) co-regulate osteoblast proliferation and mineralization.
    Dashti P; van de Peppel J; Thaler R; Paradise CR; Stein GS; Montecino MA; van Leeuwen JPTM; van der Eerden BJ; Dudakovic A; van Wijnen AJ
    Gene; 2023 Jan; 851():146928. PubMed ID: 36191822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2.
    Abu-Farha M; Lanouette S; Elisma F; Tremblay V; Butson J; Figeys D; Couture JF
    J Mol Cell Biol; 2011 Oct; 3(5):301-8. PubMed ID: 22028380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.
    Brown MA; Sims RJ; Gottlieb PD; Tucker PW
    Mol Cancer; 2006 Jun; 5():26. PubMed ID: 16805913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone methyltransferase Smyd2 is a negative regulator of macrophage activation by suppressing interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) production.
    Xu G; Liu G; Xiong S; Liu H; Chen X; Zheng B
    J Biol Chem; 2015 Feb; 290(9):5414-23. PubMed ID: 25583990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
    Xu S; Zhong C; Zhang T; Ding J
    J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
    Yi X; Jiang XJ; Fang ZM
    Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMYD2 Drives Mesendodermal Differentiation of Human Embryonic Stem Cells Through Mediating the Transcriptional Activation of Key Mesendodermal Genes.
    Bai HJ; Zhang P; Ma L; Liang H; Wei G; Yang HT
    Stem Cells; 2019 Nov; 37(11):1401-1415. PubMed ID: 31348575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
    Komatsu S; Ichikawa D; Hirajima S; Nagata H; Nishimura Y; Kawaguchi T; Miyamae M; Okajima W; Ohashi T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Imoto I; Inazawa J; Otsuji E
    Br J Cancer; 2015 Jan; 112(2):357-64. PubMed ID: 25321194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMYD2 suppresses APC2 expression to activate the Wnt/β-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.
    Meng F; Liu X; Lin C; Xu L; Liu J; Zhang P; Zhang X; Song J; Yan Y; Ren Z; Zhang Y
    Am J Cancer Res; 2020; 10(3):997-1011. PubMed ID: 32266106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation.
    Wang L; Li L; Zhang H; Luo X; Dai J; Zhou S; Gu J; Zhu J; Atadja P; Lu C; Li E; Zhao K
    J Biol Chem; 2011 Nov; 286(44):38725-38737. PubMed ID: 21880715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
    Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
    Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
    Ohtomo-Oda R; Komatsu S; Mori T; Sekine S; Hirajima S; Yoshimoto S; Kanai Y; Otsuji E; Ikeda E; Tsuda H
    Hum Pathol; 2016 Mar; 49():145-55. PubMed ID: 26826421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
    Xu W; Chen F; Fei X; Yang X; Lu X
    Med Sci Monit; 2018 Oct; 24():7357-7365. PubMed ID: 30319138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
    Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
    J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.
    Li J; Wan F; Zhang J; Zheng S; Yang Y; Hong Z; Dai B
    Mol Carcinog; 2023 Jul; 62(7):940-950. PubMed ID: 37036190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.